Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications

Abstract

Intratumour heterogeneity (ITH) can impair the precise molecular analysis of tumours and may contribute to difficulties encountered in cancer biomarker qualification and treatment personalisation.